Evidence map›Paper›PMID 36879168›Full record

ArticleBiotechnology letters2023

Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain.

Dezhou Li, Guosheng Gao, Bo Zhu, Jingjing Ying

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Dezhou Li *Department of Infection Diseases, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Guosheng Gao *Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Bo ZhuNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Jingjing YingNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China. yingjingjing0616@163.com.ORCID http://orcid.org/0000-0002-3466-3377
University of Chinese Academy of Sciences · CNBlood Center of Zhejiang Province · CNWangjing Hospital of China Academy of Chinese Medical Sciences · CN

Funding

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College 2019HMKY17Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province 2019E10020Key Medical Subjects of Joint Construction Between Provinces and Cites (Infectious Diseases), China 2016017
6 · The paper itself

Abstract

objectiveThrombopoietin mimetic peptide (TMP), an analog of natural thrombopoietin, can be used to treat primary immune thrombocytopenia. However, the short half-life of TMP limits its application in clinics. The present study aimed to improve the stability and biological activity of TMP in vivo via genetic fusion to the albumin-binding protein domain (ABD).

resultsTMP dimer was genetically fused to the N-terminal or C-terminal of ABD, denoted as TMP-TMP-ABD and ABD-TMP-TMP. A Trx-tag was used to improve the fusion proteins' expression levels effectively. ABD-fusion TMP proteins were produced in Escherichia coli and purified by Ni

conclusionsABD can effectively improve the stability and pharmacological activity of TMP by binding to serum albumin, and the ABD-fusion TMP protein can promote platelet formation in vivo.

Indexed as

PeptidesSerum AlbuminAnimalsEscherichia coliHalf-LifeMiceRecombinant Fusion ProteinsPeptidesRecombinant Fusion ProteinsSerum Albuminthrombopoietin mimetic peptideAlbumin-binding domainEscherichia coliSerum albuminThrombopoietin mimetic peptide

Identifiers

PMID36879168
OpenAlexW4323322668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.